A higher prevalence of adults with CKD reported sleep-related problems (sleep disorder, trouble sleeping, and nocturia) than adults without CKD. Among adults without or with CKD, prevalence of self-reported sleep disorders trended higher over time. Nocturia is more commonly reported in adults with CKD than those without CKD.
To view the prevalence of the three different sleep-related problems, select from the drop-down menu below. Sleep-related problems include sleep disorder, trouble sleeping, and nocturia.
A sleep disorder is defined as a self-reported positive response to the question: “Ever told by doctor have sleep disorder?”. Sleep disorder data are not available for the 2017–March 2020 cycle. Trouble sleeping is defined as a self-reported positive response to the question: “Ever told doctor had trouble sleeping?”. Data are not adjusted.
NHANES is a nationally representative, cross-sectional survey that is currently conducted every two years (since 1999) by CDC's National Center for Health Statistics among noninstitutionalized US civilian residents. The survey consists of a standardized in-home interview and a physical examination with blood and urine collected at a mobile examination center. Data were examined by combining two NHANES cycles to represent four-year periods from 2001 to 2016 and the 2017–March 2020 pre-pandemic cycle.
Note: Not all NHANES variables are collected for all years; therefore, some NHANES indicators may not utilize the full 20-year span.
Prevalence of self-reported sleep-related problems among U.S. adults.
National Health and Nutrition Examination Survey (NHANES).
Noninstitutionalized U.S. adults aged ≥ 18 years (sleep disorder and trouble sleeping) and ≥ 20 years (nocturia), pregnant women excluded.
2005–March 2020.
Adults aged ≥ 18 years who self-reported having a sleep disorder or trouble sleeping; adults aged ≥ 20 years who self-reported nocturia.
Adults aged ≥ 18 years with complete serum creatinine and urine albumin measurements who completed the sleep disorders questionnaire.
CKD is defined by an estimated glomerular filtration rate (eGFR) < 60 ml/min/1.73 m² or albuminuria (urine albumin to creatinine ratio [UACR] ≥ 30 mg/g). Stage 1: eGFR ≥ 90 ml/min/1.73 m² and albuminuria; stage 2: eGFR 60–89 ml/min/1.73 m² and albuminuria; stage 3: eGFR 30–59 ml/min/1.73 m²; stage 4: 15–29 ml/min/1.73 m²; stage 5: eGFR < 15 ml/min/1.73 m². Estimates are based on single estimates of eGFR and UACR.
Based on the CKD-EPI (2021) equation for calibrated creatinine: eGFR=142 x [min(serum creatinine in mg/dL) /κ, 1)]**α x [max(serum creatinine/κ, 1)]**-1.20 x 0.9938**age x (1.012 if female). κ = 0.7 if female and 0.9 if male α = -0.241 if female and -0.302 if male ** = raise to the power
UACR is calculated as urine albumin divided by urine creatinine. Albuminuria is defined as UACR ≥ 30 mg/g.
Serum creatinine values used for lculation are standardized against isotope dilution mass spectrometry (IDMS).
Measured in random urine collection by fluorescent immunoassay.
Self-reported affirmative response to the question: “Ever told by doctor have sleep disorder?”
Self-reported affirmative response to the question: “Ever told doctor had trouble sleeping?”
Self-reported response of two or more times to the question: “During the past 30 days, how many times per night did you most typically get up to urinate, from the time you went to bed at night until the time you got up in the morning?”
Data are self-reported and diagnosis information for sleep disorders is not available.
Appropriate NHANES survey weights are used for all analyses; if the relative standard error is greater than 30%, the estimates are not shown. Serum creatinine measurements are assay corrected for NHANES years 2005 and 2006 and prior to be combined with later years.